## Mini basket to go here ##
About us
We are a pharmaceutical company spun out of the University of Sunderland, committed to the development of effective medicinal treatments in therapeutic areas where there is unmet clinical need.
Core values
We are driven by a fresh perspective to pair technical expertise with compassion to build an organisation that supports our communities. We are dedicated to creating profound positive societal benefit to patients and the healthcare community, engaging in drug discovery and development to bring to market products that:
Target real unmet clinical need
Are cost effective
Offer greater prescriber and patient choice in circumstances where there are:
Limited treatment options available
Where treatment options are restricted on the basis of cost
Active Projects
Sundara Pharma is developing a novel treatment for Nephropathic Cystinosis and a pipeline of novel compounds as sustainable treatments for diseases in a variety of therapeutic areas.
Cystinosis in numbers
60%
Expected rate of growth in untreated children with cystinosis1
22.7%
Of Cystinosis patients were found to be fully compliant with Cystagon therapy22
5%
Of all childhood cases of kidney failure are due to Cystinosis11
CF10 – CystinosisAbout Cystinosis
1 National Organisation for Rare Disorders 2021, Cystinosis, National Organisation for Rare Disorders, viewed 13th January 2021, https://rarediseases.org/rare-diseases/cystinosis/
2 Levtchenko et al. Strict Cysteamine dose regimen is required to prevent nocturnal cystine accumulation in cystinosis. Pediatric Nephrology. 2006;21:110.
SUBSCRIBE
Receive updates and news